Core Viewpoint - The announcement provides an update on the conversion results of the "Shou 22 Convertible Bond" and the changes in the company's share capital as of March 31, 2025, highlighting the low conversion rate and the remaining unconverted bond amount. Group 1: Conversion Status - From May 23, 2023, to March 31, 2025, the total amount converted from the "Shou 22 Convertible Bond" is 309,000 yuan, accounting for 0.0776% of the total issuance [2][5] - The total number of shares formed from the conversion is 8,097 shares, representing 0.0041% of the company's total shares before conversion [2][5] - As of March 31, 2025, the amount of "Shou 22 Convertible Bond" that has not been converted is 397,691,000 yuan, which constitutes 99.92% of the total issuance [2][6] Group 2: Recent Quarter Conversion - In the first quarter of 2025, from January 1 to March 31, the cumulative conversion amount is 1,000 yuan, which is 0.0003% of the total convertible bond issuance [2][5] - The number of shares formed during this period is 26 shares, accounting for 0.00001% of the total shares before conversion [2][5] Group 3: Bond Issuance Overview - The "Shou 22 Convertible Bond" was approved for issuance on November 17, 2022, with a total issuance of 39.8 million yuan, consisting of 398,000 bonds at a face value of 100 yuan each [3] - The bond has a six-year term with a tiered interest rate starting from 0.5% in the first year to 2.5% in the sixth year [3] Group 4: Conversion Price Adjustments - The initial conversion price was set at 38.08 yuan per share, which was adjusted to 37.65 yuan on July 4, 2023, and further adjusted to 37.27 yuan on June 20, 2024, and finally to 37.11 yuan on July 8, 2024, due to various corporate actions [4]
浙江寿仙谷医药股份有限公司关于“寿22转债”转股结果暨股份变动的公告